Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M44.8Revenue (TTM) $M47.8Net Margin (%)-149.0Altman Z-Score-4.3
Enterprise Value $M136EPS (TTM) $-7.0Operating Margin %-183.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-0.8Pre-tax Margin (%)-148.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-31.2Quick Ratio2.8Cash flow > EarningsN
Price/Sales1.05-y EBITDA Growth Rate %-32.1Current Ratio3.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-22.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-288.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M15.2ROIC % (ttm)-74.3Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OREX is held by these investors:



OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Moglia Stephen A.VP, Chief Accounting Officer 2016-12-19Sell800$1.9650view
Booth Mark DChief Commercial Officer 2015-02-26Sell5,000$56.8-94.82view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell2,264$60-95.1view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell3,139$58.3-94.96view
BOCK LOUIS CDirector 2014-11-18Buy133$55.8-94.73view
BOCK LOUIS CDirector 2014-11-12Buy2,705$55.7-94.72view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell30,000$44.7-93.42view
NARACHI MICHAELPresident and CEO 2014-09-15Buy5,000$47.8-93.85view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy500$46.9-93.73view
Hagan Joseph PChief Business Officer 2013-07-31Sell1,200$78-96.23view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Orexigen Announces Activities at European Congress on Obesity 2017 May 16 2017 
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 May 09 2017 
Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcar May 02 2017 
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA May 02 2017 
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on Apr 25 2017 
Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada Apr 25 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Po Apr 05 2017 
Seth Klarman’s Largest New Buys and Adds Feb 15 2016 
Value Investing in BioPharma Nov 18 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 

More From Other Websites
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio May 24 2017
The 3 Best Obesity-Drug Stocks to Buy in 2017 May 19 2017
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth May 17 2017
Orexigen Announces Activities at European Congress on Obesity 2017 May 16 2017
Edited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT May 10 2017
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y May 10 2017
Orexigen reports 1Q loss May 09 2017
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 May 09 2017
Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call May 09 2017
Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch... May 02 2017
ETFs with exposure to Orexigen Therapeutics, Inc. : May 2, 2017 May 02 2017
Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of... May 02 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA... May 02 2017
Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics Apr 28 2017
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on... Apr 25 2017
Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada Apr 25 2017
ETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017 Apr 17 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for... Apr 05 2017
Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017 Mar 31 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)